Skip to main content

Companion Diagnostics Market Size Worth USD 15.91 billion by 2029 | Report by Fortune Business Insight

According to Fortune Business Insights, Companion Diagnostics Market size was valued at USD 6.80 billion in 2021. The market is projected to grow from USD 7.67 billion in 2022 to USD 15.91 billion by 2029, exhibiting a CAGR of 11.0% during the forecast period.

Pune, India, Jan. 10, 2023 (GLOBE NEWSWIRE) — The global companion diagnostics market size was valued at USD 6.80 billion in 2021. The market is projected to grow from USD 7.67 billion in 2022 to USD 15.91 billion by 2029, exhibiting a CAGR of 11.0% during the forecast period.

This information is provided by Fortune Business Insights, in its report titled, “Companion Diagnostics Market, 2022-2029.”

Get Sample PDF Brochure:

https://www.fortunebusinessinsights.com/enquiry/sample/companion-diagnostics-market-107097


Companion Diagnostics Market Report Scope & Segmentation :

Report Coverage Details
Forecast Period 2022 to 2029
Forecast Period 2022 to 2029 CAGR 11.0%
2029 Value Projection USD 15.91 Billion
Base Year 2021
Market Size in 2021 USD 6.80 Billion
Historical Data for 2018 to 2020
No. of Pages 135


Driving Factors

Rising Cancer Incidence to Accelerate Market Growth

The number of cancer patients has significantly increased in recent years. The prevalence of cancer cases is rising, which increases the need for effective CDx assays. Genomic testing provides clinicians with precise information on the treatment protocols and presents a complete picture of patients’ tumors. Sales of CDx products are thus rising as cancer incidence rises.

To accommodate the increased demand, additional tests are also being developed to identify certain kinds of mutations. This factor has raised the demand for these tests on a global level and will continue to fuel the companion diagnostics market growth in the near future.

COVID-19 Impact

Drop in Number of Tests Carried Out during COVID-19 Owing to Decrease in Diagnosis of Cancer

Since the outbreak of COVID-19, companion diagnostics have become less necessary. Major market participants also suffered a sizable loss in revenue as a result of the COVID-19 pandemic and other problems such as decline in testing volume. The market’s revenue growth in 2020 was lower than in 2019, declining to 1.5% from 8.5%.

To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit:

https://www.fortunebusinessinsights.com/companion-diagnostics-market-107097


Segments

Polymerase Chain Reaction Segment to Dominate Backed by Launch of New Products

Based on technology, the polymerase chain reaction dominated the market in 2021, owing to the introduction of new products in the market by the key players.

Increasing Prevalence of Cancer and the Emphasis of Key Players on Innovative Technology Development Led to the Dominance of the Segment

In terms of indication, the cancer segment is anticipated to exhibit a dominant companion diagnostics market share due to the increasing prevalence of cancer & key players’ focus on innovative technology to develop advance tests for cancer drugs.

Quick Buy – Companion Diagnostics Market Research Report:

https://www.fortunebusinessinsights.com/checkout-page/107097


Collaborations with Manufacturers Leading to the Significant Share of the Pharmaceutical & Biopharmaceutical Companies Segment

The pharmaceutical & biopharmaceutical companies generated the highest revenue in the market in 2021. Collaborations with companion diagnostics manufacturers led to the dominance of this segment.

Geographically, the market is segregated into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Report Coverage

The report presents a holistic study of the market along with current trends and future anticipations to establish proximate investment gains. An in-depth analysis of any upcoming opportunities, threats, competitions or driving factors is also mentioned in the report.

Speak To Our Analyst: 

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/companion-diagnostics-market-107097


Regional Insights

North America to Lead Backed by Higher Occurrence of Cancer Patients

In 2021, North America produced USD 2.35 billion in revenue. The dominance of the region is linked to its higher incidence of cancer and other chronic diseases as well as to its expanding use of sophisticated CDx assays.

Europe is projected to rank as the second-most significant region in terms of revenue in the global market in 2021. The expansion of cooperation between local pharmaceutical firms and companion diagnostics producers is credited with the region’s success.

During the forecast period, Asia Pacific is anticipated to develop at the greatest CAGR. This element is related to the increased incidence of cancers, the expansion of the healthcare industry, and the rise in the number of businesses producing medical devices for diagnostic purposes.

Competitive Landscape

Collaborations amongst Businesses to Protect their Brand Values in the Global Market

Market leaders regularly choose efficient tactics to advertise their goods and fortify their positions in the industry. One such tactic is to collaborate with other businesses to launch new products in order to reach more end-users.

Key Industry Development

June 2022: In partnership with OmniSeq Corporation, Laboratory Corporation of America Holdings introduced OmniSeq INSIGHTsm, a complete genomic and immunological profiling tissue-based test utilizing Next-Generation Sequencing (NGS) technology. The test is intended to enhance patient outcomes and develop precision oncology.

List of Key Players Covered in the Report

  • Abbott (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Agilent Technologies, Inc. (U.S.)
  • Illumina, Inc. (U.S.)
  • Guardant Health (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • BIOMERIEUX (France)
  • QIAGEN (Germany)
  • Myriad Genetics, Inc. (U.S.)

Ask for Customization of this Report:

https://www.fortunebusinessinsights.com/enquiry/customization/companion-diagnostics-market-107097


Table Of Contents :

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
    • Market Trends
  • Key Insights
    • Incidence of Cancer, Key Countries, 2021
    • Technological Advancements of Companion Diagnostics
    • New Product Launches, By Key Players
    • Key Industry Developments – Mergers & Acquisition
    • Impact of COVID-19 on the Market
  • Global Companion Diagnostics Market Analysis, Insights and Forecast, 2018-2029
    • Market Analysis, Insights and Forecast – By Technology
      • Polymerase Chain Reaction
      • Immunohistochemistry
      • In-situ Hybridization
      • Next Generation Gene Sequencing
      • Others
    • Market Analysis, Insights and Forecast – By Indication
      • Cancer
      • Neurological Diseases
      • Infectious Diseases
      • Others
    • Market Analysis, Insights and Forecast – By End user
      • Pharmaceutical & Biopharmaceutical Companies
      • Reference Laboratories
      • Contract Research Organization
    • Market Analysis, Insights and Forecast – By Region
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East and Africa
  • North America Companion Diagnostics Market Analysis, Insights and Forecast, 2018-2029
    • Market Analysis, Insights and Forecast – By Technology
      • Polymerase Chain Reaction
      • Immunohistochemistry
      • In-situ Hybridization
      • Next Generation Gene Sequencing
      • Others
    • Market Analysis, Insights and Forecast – By Indication
      • Cancer
      • Neurological Diseases
      • Infectious Diseases
      • Others
    • Market Analysis, Insights and Forecast – By End user
      • Pharmaceutical & Biopharmaceutical Companies
      • Reference Laboratories
      • Contract Research Organization
    • Market Analysis, Insights and Forecast – By Country
      • U.S.
      • Canada
  • Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2018-2029
    • Market Analysis, Insights and Forecast – By Technology
      • Polymerase Chain Reaction
      • Immunohistochemistry
      • In-situ Hybridization
      • Next Generation Gene Sequencing
      • Others
    • Market Analysis, Insights and Forecast – By Indication
      • Cancer
      • Neurological Diseases
      • Infectious Diseases
      • Others
    • Market Analysis, Insights and Forecast – By End user
      • Pharmaceutical & Biopharmaceutical Companies
      • Reference Laboratories
      • Contract Research Organization  
    • Market Analysis, Insights and Forecast – By Country/ Sub-region
      • Germany
      • U.K
      • France
      • Italy
      • Spain
      • Scandinavia
      • Rest of Europe

Toc Continue…


Explore Our Trending Reports of Fortune Business Insight’s Healthcare Market Reports :

Ventricular Assist Device Market Size, Share, Demands & Growth [2028]

US Bone Void Fillers Market Size, Share, Demands | Growth Report [2022-2029]

Milk Mineral Concentrate Market Size, Share, Demands & Growth | Report [2029]

Cancer Vaccines Market Size & Share | Global Report [2029]

Veterinary Anesthesia Equipment Market Size, Share, Demands & Growth [2028]


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.